Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S
出版年份 2020 全文链接
标题
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S
作者
关键词
-
出版物
TUMORI
Volume -, Issue -, Pages 030089162093080
出版商
SAGE Publications
发表日期
2020-06-11
DOI
10.1177/0300891620930803
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients
- (2018) Michael Davidson et al. Clinical Colorectal Cancer
- Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies
- (2018) Alessandra Raimondi et al. PHARMACOGENOMICS
- Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis
- (2017) Jinxin Shi et al. Scientific Reports
- Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
- (2016) E. An et al. ANNALS OF ONCOLOGY
- PS01.30: Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non–Small Cell Lung Cancer
- (2016) Maria Toki et al. Journal of Thoracic Oncology
- Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer
- (2015) Maria Di Bartolomeo et al. Gastric Cancer
- Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues
- (2015) Carine Steiner et al. MOLECULAR & CELLULAR PROTEOMICS
- High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
- (2015) Paolo Nuciforo et al. Molecular Oncology
- Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study
- (2015) ZHI-LIANG HUANG et al. Oncology Letters
- Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
- (2014) E. Bajetta et al. ANNALS OF ONCOLOGY
- Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapy
- (2014) Zheng Li et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer
- (2014) Jingwei Yu et al. EUROPEAN JOURNAL OF CANCER
- Genetic markers for prediction of treatment outcomes in ovarian cancer
- (2014) E Caiola et al. PHARMACOGENOMICS JOURNAL
- Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue
- (2014) Daniel V. T. Catenacci et al. PLoS One
- Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges
- (2014) Rosalba Miceli WORLD JOURNAL OF GASTROENTEROLOGY
- Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer
- (2013) Jun-Eul Hwang et al. BMC CANCER
- Application of Selected Reaction Monitoring for Multiplex Quantification of Clinically Validated Biomarkers in Formalin-Fixed, Paraffin-Embedded Tumor Tissue
- (2013) Todd Hembrough et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer
- (2013) Vladimir M. Moiseyenko et al. MEDICAL ONCOLOGY
- Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting
- (2012) Lisa M. McShane et al. JOURNAL OF CLINICAL ONCOLOGY
- Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials
- (2011) T. Reiman et al. ANNALS OF ONCOLOGY
- Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel
- (2011) Jing Gao et al. BMC CANCER
- Expressions of thymidylate synthase, thymidine phosphorylase, class III β-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin
- (2011) Ming Lu et al. Chinese Journal of Cancer Research
- Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?
- (2011) M. Mariani et al. CURRENT MOLECULAR MEDICINE
- Drugs that target dynamic microtubules: A new molecular perspective
- (2011) Richard A. Stanton et al. MEDICINAL RESEARCH REVIEWS
- Class III -Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
- (2010) G. Ploussard et al. CANCER RESEARCH
- Randomized Clinical Trials With Biomarkers: Design Issues
- (2010) B. Freidlin et al. JNCI-Journal of the National Cancer Institute
- Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
- (2010) Ilfet Songun et al. LANCET ONCOLOGY
- Class III -tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma
- (2009) Y. Koh et al. ANNALS OF ONCOLOGY
- Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
- (2009) R. M. Simon et al. JNCI-Journal of the National Cancer Institute
- Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
- (2009) E. A. Perez MOLECULAR CANCER THERAPEUTICS
- Proteomic Analysis of Laser-Captured Paraffin-Embedded Tissues: A Molecular Portrait of Head and Neck Cancer Progression
- (2008) V. Patel et al. CLINICAL CANCER RESEARCH
- Class III -Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel
- (2008) C. M. Galmarini et al. CLINICAL CANCER RESEARCH
- Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
- (2008) Pascal Sève et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More